

Interests Register

Thyroid cancer Advisory Committee

Register last updated: 30 November 2022

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Richard Grünewald	Committee Chair	Direct, financial	Private practice (medicolegal services). Very small part of practice, involving only medicolegal reporting on neurological injuries (about 30/year)	2000	On application	Ongoing	Non-specific Declare and participate
Richard Grünewald	Committee Chair	Direct, financial	Received support from Ipsen pharma to attend a conference in Copenhagen on botulinum toxins and their use in the management of neurological disorders in January 2019. The monetary value of this support was about £1000.	January 2019	On application	January 2019	Non-specific Declare and participate
Jeremy Davis	Committee Topic Adviser	Direct, non-financial, professional and personal	President, British Association of Endocrine and Thyroid Surgeons (BAETS)	October 2019	On application	October 2021	Non-specific Declare and participate
Jeremy Davis	Committee Topic Adviser	Direct, non-financial, professional and personal	Trustee, British Thyroid Foundation	July 2019	On application	October 2021	Non-specific Declare and participate.

Jeremy Davis	Committee Topic Adviser	Direct, non-financial, professional and personal	Chair, KENT and Medway Thyroid Cancer network group (TSSG), Kent and Medway cancer collaborative	October 2018	On application	September 2022	Non-specific Declare and participate
Jeremy Davis	Committee Topic Adviser	Direct, financial	Private practice –most of my clinical practice in thyroid related disease is NHS, but I do see some private patients. I follow the same diagnostic and therapeutic pathways as my NHS practice, based on BTA 2014 guidelines. I see about four thyroid cancer patients per year.	January 1998	On application	October 2022	Specific. Only a few private patients seen related to thyroid cancer. Declare and participate
Jeremy Davis	Committee Topic Adviser	Direct, non-financial, professional and personal	Clinical managerial role as Clinical Director of Cancer care services at my main employing trust (Medway, NHS Foundation Trust).	November 2020	20 November 2020	September 2022	Non-specific Declare and participate
Jeremy Davis	Committee Topic Adviser	Direct, non-financial, professional and personal	Co-author of the following paper, which has been accepted for publication. Relates to thyroid, but not to the work of the guideline committee. Management of haematoma after thyroid surgery: systematic review and multidisciplinary consensus guidelines from the Difficult Airway Society, the British Association of Endocrine and Thyroid Surgeons and the British Association of Otorhinolaryngology, Head and Neck Surgery.	September 2021	22 September 2021		Non-specific Declare and participate

Jeremy Davis	Committee Topic Adviser	Direct, non-financial, professional and personal	Co-author of the following paper, which has been accepted for publication. Relates to thyroid, but not to the work of the guideline committee. The United Kingdom thyroid multi-disciplinary team: A national survey of services and comparison to guidelines	September 2021	22 September 2021		Non-specific Declare and participate
John Buscombe	Committee Member	Direct, non-financial, professional and personal	President and Trustee, British Nuclear Medicine Society	April 2018	4 March 2020	2021	Non-specific Declare and participate
John Buscombe	Committee Member	Direct, non-financial, professional and personal	Member of the Nuclear Medicine Specialty Committee of the Royal College of Physicians. As part of this role I have made comments on NICE guidelines. I am aware I will not be able to comment on the thyroid cancer guidelines if I am still in this role.	1997	4 March 2020	2021	Non-specific Declare and participate
John Buscombe	Committee Member	Direct, non-financial, professional and personal	Member of the Inter Collegiate Standing Committee on Nuclear Medicine (ICSCNM)	2017	4 March 2020	2021	Non-specific Declare and participate
John Buscombe	Committee Member	Direct, financial	Consultancy role for Advanced Accelerator Applications (AAA). This is related to the treatment of Neuroendocrine tumours (NETs). This company does not make anything to do with thyroid cancer	2019	4 March 2020	Ongoing	Non-specific Declare and participate

John Buscombe	Committee Member	Direct, financial	Gave and attended lectures organised by Boston BTG (now Boston Scientific). This company does not have products related to the diagnosis or treatment of thyroid cancer. Most recent lecture given December 2019 which was unpaid in the end.	2012	4 March 2020	Ongoing	Non-specific Declare and participate
John Buscombe	Committee Member	Direct, non-financial	Attended lectures on treatment of colon liver metastases in the liver and hepatocellular cancer organised by Sirtex Medical. This company provides treatment options for liver cancer patients. Travel costs and hotel stay paid for by Sirtex.	2 March 2020	4 March 2020	Ongoing	Non-specific Declare and participate
John Buscombe	Committee Member	Direct, non-financial, professional and personal	Co-author of Dizdarevic S, Tulchinsky M, McCready VR, Mihailovic J, Vinjamuri S, Buscombe JR, Lee ST, Frangos S, Sathekge M, Siraj Q, Choudhury P. The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma. World Journal of Nuclear Medicine. 2019 Apr;18(2):123. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476239/	2019	2 October 2020		Non-specific. Declare and participate.
John Buscombe	Committee Member	Direct, non-financial, professional and personal	Buscombe J. Radioiodine and its relationship to hematologic malignancy: The confounding role of supraphysiologic thyroxine. J Clin Oncol. 2018 Jun 20;36:1884-5. Review of a study. https://ascopubs.org/doi/full/10.1200/JCO.2018.78.0395	2018	2 October 2020		Non-specific Declare and participate
John Buscombe	Committee Member	Direct, financial	Delivered a talk for Eisai pharmaceuticals about the role of nuclear medicine in differentiated thyroid cancer to their oncology sales team. The talk was limited to discussing radioiodine and PET imaging.	23 November 2021	4 November 2021	23 November 2021	Specific. Eisai do not sell anything related to radioiodine or PET

			Eisai do not make or sell anything which is used in radioiodine or PET. Payment was received for the lecture.				and committee member did not discuss the content of the guideline. Declare and participate
Preetha Chengot	Committee Member	Direct, financial	Private diagnostic histopathology reporting practice. I do half a day per week, about 10% of my private reporting work is thyroids. I report those using the same Royal College of Pathologist guidelines and criteria as I do for my NHS thyroid cases. Small amount of cases.	October 2013	On application	Ongoing	Specific. Only a few private patients seen related to thyroid cancer. Declare and participate.
Preetha Chengot	Committee Member	Direct, non-financial, professional and personal	Joined the National Cancer Research Institute (NCRI) thyroid cancer subgroup.	16 January 2021	22 February 2021	Ongoing	Non-specific Declare and participate
Preetha Chengot	Committee member	Direct, non-financial, professional and personal	I am a member of the UK Endocrine Pathology Society (UKEPS) Committee since February 2022. This is an unpaid role. I did not contribute/participate in the stakeholder comments from UKEPS to avoid conflict of interest.	11 September 2022	February 2022	Ongoing	Non-specific Declare and participate
Neil Cozens	Committee Member	Direct, financial	Undertakes a small amount (maximum of 0.5 days per week) of private medical practice, within the same area of expertise as NHS work. Approximately 6-8 ultrasounds per week privately (excluding holiday times) with a maximum of half of these (usually less) being primarily thyroid scans. The number of Fine Needle Aspirates for thyroid patients is in single figures per year, usually no more than about half a	1996	On application	Ongoing	Specific. Only a few private patients seen related to thyroid cancer. Declare and participate

			dozen. Receives referrals directly from clinicians he works with within NHS practice.				
Neil Cozens	Committee Member	Direct, non-financial, professional and personal	I have joined the committee for forthcoming update to the British Thyroid Association guidelines for management of thyroid cancer	April 2021	27 April 2021	Ongoing	Specific. The guidelines will be produced collaboratively by consensus. Declare and participate
Aimee Di Marco	Co-opted Committee Member	Direct, financial	I undertake private practice in endocrine surgery, one session per week, which includes looking after patients with thyroid nodules and thyroid cancer. However, I do not receive any financial benefit / incentive for thyroid molecular testing. Have only discussed using molecular testing once (1 patient) in the last 6 months.	2019	On application	Ongoing	Specific. Only a few private patients seen related to molecular testing in thyroid cancer. Declare and participate.
Aimee Di Marco	Co-opted Committee Member	Direct, non-financial, professional and personal	Honorary Senior Lecturer, Imperial College, London. I am the lead for Anatomy & Diagnostics in the undergraduate curriculum, the lead for Surgery curriculum reform and I teach on BSc's in 'Surgical Design, Technology and Innovation' and Endocrinology.	2019	On application	Ongoing	Non-specific Declare and participate
Aimee Di Marco	Co-opted Committee Member	Direct, non-financial, professional and personal	Research project on molecular analysis of thyroid pathology: undertaking a pilot study at the Imperial NHS Trust Thyroid MDT. Will be talking on the subject at 2021 annual meeting of the British Association of Endocrine and Thyroid Surgeons.	2021	On application	Ongoing	Specific. Talk about own experiences using molecular testing and pilot study. Declare and participate

Fiona Eatock	Committee Member	Direct, non-financial, professional and personal	Treasurer and Trustee of British Association of Endocrine and Thyroid Surgeon (BAETS)	October 2017	On application	Ongoing	Non-specific Declare and participate
Fiona Eatock	Committee Member	Direct, non-financial, professional and personal	BAETS representative on Royal College of Surgeons of England Cancer Services Committee	December 2019	16 July 2020	Ongoing	Non-specific Declare and participate
Fiona Eatock	Committee Member	Direct, non-financial, professional and personal	Leading a workshop at the BAETS Masterclass on Thyroid and Parathyroid surgery. This involves MDT-type discussions on the management of complex cases in thyroid cancer.	07/03/2022	10 December 2021	07/03/2022	Non-specific Declare and participate
Kate Farnell	Committee Member	Direct, non-financial, professional and personal	CEO of the Butterfly Thyroid Cancer Trust (BTCT)	2001	On application	Ongoing	Specific Declare and participate
Kate Farnell	Committee Member	Direct, non-financial, professional and personal	Committee member on the forthcoming update to the British Thyroid Association guidelines for the management of thyroid cancer.	2020	15 July 20	Ongoing	Specific. The guidelines will be produced collaboratively by consensus. Declare and participate.

Kate Farnell	Committee Member	Direct, non-financial, professional and personal	Co-author of McIntyre C, Jacques T, Palazzo F, Farnell K, Tolley N. Quality of life in differentiated thyroid cancer. International Journal of Surgery. 2018 Feb 1;50:133-6.	2018	02 October 2020		Non-specific Declare and participate
Kate Farnell	Committee Member	Direct, non-financial, professional and personal	Co-author of Banach R, Bartès B, Farnell K, Rimmele H, Shey J, Singer S, Verburg FA, Luster M. Results of the Thyroid Cancer Alliance international patient/survivor survey: psychosocial/informational support needs, treatment side effects and international differences in care. Hormones. 2013 Jul 1;12(3):428-38.	2013	02 October 2020		Non-specific Declare and participate
Kate Farnell	Committee Member	Direct, non-financial, professional and personal	Co-author of Brown SR, Hall A, Buckley HL, Flanagan L, de Castro DG, Farnell K, Moss L, Gregory R, Newbold K, Du Y, Flux G. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC cancer. 2019 Dec 1;19(1):582.	2019	02 October 2020		Non-specific Declare and participate
Kate Farnell	Committee Member	Direct, non-financial, professional and personal	Co-author of Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn J, John R, Nutting C, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. New England Journal of Medicine. 2012 May 3;366(18):1674-85. https://www.nejm.org/doi/full/10.1056/nejmoa110958	2012	02 October 2020		Specific. Declare and participate. Role as an author was to edit the draft text to make it more patient friendly for people with thyroid cancer. Not

			9 . Non-industry funded study supported by grants from Cancer Research UK, University College London and the University College London Hospital Comprehensive Biomedical Research Centre.				involved in the analysis of results or drafting the paper.
Kate Farnell	Committee Member	Direct, non-financial, professional and personal	Co-author of Mallick U, Harmer C, Hackshaw A, Moss L, IoN Trial Management Group. Collaborators: Mallick U, Beare S, Evans C, Farnell K, Forsyth S, Gerrard G, Hackshaw A, Harmer C, Harrison B, Hyer S, Johnson SJ, Lemon C, Lewington V, Lunt C, Moss L, Newbold K, Nicol A, Nutting C, Reed N, Stephenson T, Wadsley J, Watkinson J, Yap B. Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. Clinical oncology (Royal College of Radiologists (Great Britain)). 2012 Apr;24(3):159. Trial ongoing. http://www.isrctn.com/ISRCTN80416929	2012	02 October 2020		Specific Declare and participate. Review action if study reports during guideline development.
Kate Farnell	Committee Member	Direct, non-financial, professional and personal	Co-author of Farnell KA, Bliss RD, Mallick UK. Thyroid Cancer: One Doctor-Patient Partnership—The Newcastle Butterfly Model. In Practical Management of Thyroid Cancer 2018 (pp. 21-26). Springer, Cham.	2018	02 October 2020		Non-specific Declare and participate
Kate Farnell	Committee Member	Direct, non-financial, professional and personal	Trustee of British Association of Endocrine and Thyroid Surgeon (BAETS)	11 July 2017	18 March 2022	Ongoing	Non-specific Declare and participate
Kate Farnell	Committee member	Direct, non-financial, professional	Patient advisory role on the new Scottish Thyroid Cancer Network	September 2022	13 September 2022	Ongoing	Non-specific

		and personal					Declare and participate
Sonja Hoy	Committee Member	Direct, financial	Speaker on an evening meeting for Nurses on management of tyrosine kinase inhibitor (TKI) toxicities in Thyroid Cancer organized by Eisai Ltd. Payment received for the session.	26 November 2019	On application	26 November 2019	Non-specific Declare and participate
Sonja Hoy	Committee Member	Direct, financial	Chair of an all-day nurses meeting and speaker for Sanofi Genzyme. Done during annual leave and paid for my time to do session and organise event with 2 other CNSs from the 45 colleagues across the UK as part of the Thyroid Cancer Nurses Network. Over 12 months before the start of the development of the guideline.	24 March 2019	On application	24 March 2019	Non-specific Declare and participate
Steve Hyer	Committee Member	Direct, financial	I provide 2-weekly private clinics at Spire St Anthony's Hospital for patients with endocrine disorders. Less than 10% relates to thyroid cancer.	1995	On application	Ongoing	Specific. Only a few private patients seen related to thyroid cancer. Declare and participate.
Steve Hyer	Committee Member	Direct, financial	I have received honoraria for lectures given on behalf of diabetes therapies and to attend diabetic meetings from Novo, Sanofi, Lilly, Astra Zeneca and Takeda	1995	On application	Ongoing	Non-specific Declare and participate
Steve Hyer	Committee Member	Direct, financial	Eisai training event 30th Nov 2021. I have been asked to participate in a training day for Eisai employees. My brief is to talk about the pathways of referral for thyroid cancer patients and the role of the different team members in the MDT. I will be	30 November 2021	10 November 2021	30 November 2021	Non-specific Declare and participate

			referring to published guidelines from BTA and ETA. I am not being asked to discuss any Eisai products.				
Jessica Lishak	Committee Member		Nil		On application		
Kate Newbold	Committee Member	Direct, financial	Honoraria from Eisai Ltd for discussing management of the side effects of lenvatinib. Lenvatinib is not being reviewed in this guideline.	January 2020	On application		Non-specific Declare and participate
Kate Newbold	Committee Member	Direct, financial	Honoraria from Sanofi-Genzyme for talks on vandetanib for the treatment of medullary thyroid cancer.	Not in the last 12 months.	On application		Non-specific Declare and participate
Kate Newbold	Committee Member	Direct, financial	Private practice: 2 hours per week relate to thyroid cancer, and treat about 2 people per month with radioactive iodine.	2007	On application	Ongoing	Specific. Only a few private patients seen related to thyroid cancer. Declare and participate
Kate Newbold	Committee Member	Direct, non-financial, professional and personal	Local principal investigator (PI) at the Royal Marsden for IoN trial (Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients). Trial ongoing. (https://clinicaltrials.gov/ct2/show/NCT01398085). Co-author of Mallick U, Harmer C, Hackshaw A, Moss L, IoN Trial Management Group. Collaborators: Mallick U, Beare S, Evans C, Farnell K, Forsyth S, Gerrard G, Hackshaw A, Harmer C, Harrison B, Hyer S, Johnson SJ, Lemon C, Lewington V, Lunt C, Moss L, Newbold K, Nicol A, Nutting C, Reed N, Stephenson T, Wadsley J, Watkinson J, Yap B.	2012	On application	Ongoing	Specific Declare and participate. Review action if study publishes during this guideline's development.

			Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. Clinical oncology (Royal College of Radiologists (Great Britain)). 2012 Apr;24(3):159. Trial ongoing. http://www.isrctn.com/ISRCTN80416929				
Kate Newbold	Committee Member	Direct, non-financial, professional and personal	Local PI at the Royal Marsden for SEL-I-METRY trial (Can Selumetinib make advanced thyroid cancer sensitive to radioactive iodine therapy again?). Recruitment closed September 2019. http://www.isrctn.com/ISRCTN17468602 .	2015	On application	Ongoing	Non-specific Declare and participate
Kate Newbold	Committee Member	Direct, non-financial, professional and personal	Chief investigator (CI) on an academic study at the Royal Marsden studying the role of ctDNA as a biomarker in thyroid cancer. Study is currently recruiting. https://clinicaltrials.gov/ct2/show/NCT04133870 .	2019	On application	Ongoing	Non-specific Declare and participate
Kate Newbold	Committee Member	Direct, non-financial, professional and personal	Will be local PI at the Royal Marsden for the COSMIC study which is investigating cabozantinib in patients with iodine refractory thyroid cancer who have already received first-line kinase inhibitor. https://clinicaltrials.gov/ct2/show/NCT03690388 .	2020	On application	Ongoing	Non-specific Declare and participate
Kate Newbold	Committee Member	Direct, non-financial, professional and personal	Was the local PI at the Royal Marsden for the HiLO trial (A Multicentre Randomised Trial of High- Versus Low-Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation After Surgery for Differentiated Thyroid Cancer). Non-industry funded study supported by grants from Cancer Research UK, University College London and the University College London Hospital Comprehensive Biomedical	2006	On application	2012	Specific Declare and participate. Not a main author on the study, member's input is needed to ensure the guideline has the appropriate

			<p>Research Centre. Results of which were published in 2012 (see next entry)</p> <p>Co-author on the published results for the trial: Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn J, John R, Nutting C, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. New England Journal of Medicine. 2012 May 3;366(18):1674-85. https://www.nejm.org/doi/full/10.1056/nejmoa1109589</p>				expertise in this area, the study is non-industry funded.
Kate Newbold	Committee Member	Direct, non-financial, professional and personal	Asked to chair an advisory board for Ipsen looking at iodine refractory thyroid cancer and second line drugs. I am not taking an honorarium for this.	2021	22 September 2021	2021	Non-specific Declare and participate
Iain Nixon	Committee Member	Direct, financial	Private Practice ENT Surgery. I currently do approximately 2 hours per week and have only treated 1 thyroid cancer in the private sector in my career.	2018	16 March 2020	Ongoing	Non-specific. Only a few private patients seen related to thyroid cancer. Declare and participate
Iain Nixon	Committee Member	Direct, financial	Bristol Meyer Squibb £750 honorarium for presenting on circulating tumour DNA in head and neck cancer	November 2019	16 March 2020	November 2019	Non-specific Declare and participate

Iain Nixon	Committee Member	Direct, financial	Spoke at a symposium on immune therapy for Bristol Myer Squib and was paid ~£400 honorarium.	2019	16 July 2020	2019	Non-specific Declare and participate
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Extensively published on this subject which has had some impact on national and international guidelines to date https://www.ncbi.nlm.nih.gov/pubmed/?term=nixon+i+thyroid	2013	16 March 2020		Specific See following declarations for specific studies.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Nixon IJ, Shah JP, Zafereo M, Simo RS, Hay ID, Suarez C, et al. The role of radioactive iodine in the management of patients with differentiated thyroid cancer - An oncologic surgical perspective. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2020;46(5):754-62. Review article on radioactive iodine in the management of thyroid cancer.	2020	14 July 2020		Specific. Declare and participate. Study not included in the guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Chan S, Karamali K, Kolodziejczyk A, Oikonomou G, Watkinson J, Paleri V, et al. Systematic Review of Recurrence Rate after Hemithyroidectomy for Low-Risk Well-Differentiated Thyroid Cancer. European thyroid journal. 2020;9(2):73-84.	2020	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Rovira A, Nixon IJ, Simo R. Papillary microcarcinoma of the thyroid gland: current controversies and management. Current opinion in otolaryngology & head and neck surgery.	2019	14 July 2020		Specific. Declare and participate. Study not included in

			2019;27(2):110-6. Review article on surgical treatment of thyroid cancer.				guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Nixon IJ, Simo RS, Kim D. Refining definitions within low-risk differentiated thyroid cancers. Editorial comment. Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery. 2018;43(5):1195-200. Editorial on risk stratification to help clinicians decide on treatment strategies for thyroid cancer.	2018	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Nasef HO, Nixon IJ, Wreesmann VB. Optimization of the risk-benefit ratio of differentiated thyroid cancer treatment. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2018;44(3):276-85.	2018	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Goncalves Filho J, Zafereo ME, Ahmad FI, Nixon IJ, Shaha AR, Vander Poorten V, et al. Decision making for the central compartment in differentiated thyroid cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2018;44(11):1671-8.	2018	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Asimakopoulos P, Nixon IJ. Surgical management of primary thyroid tumours. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2018;44(3):321-6. Article on whether to treat.	2018	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.

Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Shaha AR, Silver CE, Angelos P, Nixon IJ, Rodrigo JP, Sanabria A, et al. The central compartment - Center of controversy, confusion, and concern in management of differentiated thyroid cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2017;43(11):1981-4.	2017	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Wang LY, Palmer FL, Migliacci JC, Nixon IJ, Shaha AR, Shah JP, et al. Role of RAI in the management of incidental N1a disease in papillary thyroid cancer. Clinical endocrinology. 2016;84(2):292-5. Observational study	2016	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Nixon IJ, Wang LY, Ganly I, Patel SG, Morris LG, Migliacci JC, et al. Outcomes for patients with papillary thyroid cancer who do not undergo prophylactic central neck dissection. The British journal of surgery. 2016;103(3):218-25. Observational study	2016	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Nixon IJ. Well-differentiated thyroid cancer - are you overtreating your patients? Endokrynologia Polska. 2016;67(1):60-6.	2016	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial,	McNamara WF, Wang LY, Palmer FL, Nixon IJ, Shah JP, Patel SG, et al. Pattern of neck recurrence	2016	14 July 2020		Specific.

		professional and personal	after lateral neck dissection for cervical metastases in papillary thyroid cancer. Surgery. 2016;159(6):1565-71. Observational study				Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Wang LY, Palmer FL, Thomas D, Nixon IJ, Tuttle RM, Shah JP, et al. Level 7 disease does not confer worse outcome than level 6 disease in differentiated thyroid cancer. Annals of surgical oncology. 2015;22(2):441-5. Observational study.	2015	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	To K, Nixon IJ. The surgical approach to managing differentiated thyroid cancer. The Indian journal of medical research. 2016;143(6):689-95.	2016	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Wang LY, Nixon IJ, Palmer FL, Thomas D, Tuttle RM, Shaha AR, et al. Comparable outcomes for patients with pT1a and pT1b differentiated thyroid cancer: Is there a need for change in the AJCC classification system? Surgery. 2014;156(6):1484-9; discussion 9-90. Observational study.	2014	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Nixon IJ, Shah JP. Well differentiated thyroid cancer: are we over treating our patients? European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British	2014	14 July 2020		Specific. Declare and participate. Study not included in

			Association of Surgical Oncology. 2014;40(2):129-32.				guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Nixon IJ, Ganly I, Shah JP. Thyroid cancer: surgery for the primary tumor. Oral oncology. 2013;49(7):654-8.	2013	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Nixon IJ, Ganly I. Radioactive iodine use in patients with low- and intermediate-risk papillary thyroid cancer. Future oncology (London, England). 2013;9(7):921-3.	2013	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012;151(4):571-9. Observational study.	2012	14 July 2020		Specific. Declare and participate. Study not included in guideline evidence review.
Iain Nixon	Committee Member	Direct, non-financial, professional and personal	I have been asked to be involved as lead author on another UK set of guidelines for the management of thyroid cancer. These multidisciplinary guidelines are published every few years. I have submitted information on the methodology of the proposed guidelines	2021	5 January 2021		Specific. The guidelines will be produced collaboratively by consensus. Declare and participate.

Nicholas Reed	Committee Member	Direct, financial	Ipsen consultancy and lecturing in relation to thyroid cancer drugs. Thyroid cancer drugs are not being covered by this guideline.	2016	On application	Ongoing	Non-specific Declare and participate.
Nicholas Reed	Committee Member	Direct, financial	Novartis (AAA) consultancy and lecturing in relation to thyroid cancer drugs. Thyroid cancer drugs are not being covered by this guideline.	2016	On application	Ongoing	Non-specific Declare and participate.
Nicholas Reed	Committee Member	Direct, financial	Eisai advisory board and lecturing in relation to thyroid cancer drugs. Thyroid cancer drugs are not being covered by this guideline.	2017	On application	Ongoing	Non-specific Declare and participate.
Nicholas Reed	Committee Member	Direct, non-financial, professional and personal	Chair of Molecular Pathology Evaluation Programme (MPEP) NHS Scotland	2018	On application	Ongoing	Non-specific Declare and participate.
Nicholas Reed	Committee Member	Direct, non-financial, professional and personal	Member of the Molecular Pathology Consortium NHS Scotland, parent committee to MPEP and reports to NSD (National Services Division).	2018	On application	Ongoing	Non-specific Declare and participate.
Nicholas Reed	Committee Member	Direct, non-financial, professional and personal	Previously advised on NICE and HTA reports including thyroid cancer, NETs and ovarian cancer	2018	On application	2019	Non-specific Declare and participate.
Nicholas Reed	Committee Member	Direct, non-financial,	Data monitoring committee for Sel-i-metry study investigating the potential clinical benefit of	2019	On application	Ongoing	Non-specific

		professional and personal	Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy				Declare and participate.
Nicholas Reed	Committee Member	Direct, non-financial, professional and personal	EORTC Thyroid Cancer Study Group member of the clinical investigators group. Unpaid activity	2019	On application	Ongoing	Non-specific Declare and participate.
Nicholas Reed	Committee Member	Direct, non-financial, professional and personal	Chief investigator (UK) for the Lilly funded trial LIBRETTO comparing selpercatinib with standard therapy in ret mutated thyroid cancer patients (both PTC and MTC). Unpaid activity.	2019	On application	Ongoing	Non-specific Declare and participate.
Nicholas Reed	Committee Member	Direct, non-financial, professional and personal	Investigator in the Exelixis funded trial COSMIC looking into cabozantinib in relapsed thyroid cancer. Unpaid activity. We have failed to recruit any patients.	2019	On application	Ongoing	Non-specific Declare and participate.
Nicholas Reed	Committee Member	Direct, non-financial, professional and personal	Reed N, Glen H, Gerrard G, Good J, Lei M, Lyon AR, Strachan M, Wadsley J, Newbold K. Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer. Clin Oncol (R Coll Radiol). 2020 May;32(5):e145-e153. doi: 10.1016/j.clon.2019.11.010. Drugs not covered by the guideline.	2020	On application		Non-specific Declare and participate.
Nicholas Reed	Committee Member	Direct, financial	Roche Advisory Board. Thyroid cancer drugs are not being covered by this guideline.	2020	On application	Ongoing	Non-specific Declare and participate.

Nicholas Reed	Committee Member	Direct, non-financial, professional and personal	Member of the National Cancer Medicines Advisory Group (NCMAG) (previously Off Babel Cancer Medicines Committee) (Health Improvement Scotland – HIS)	2020	On application	Ongoing	Non-specific Declare and participate.
Nicholas Reed	Committee Member	Direct, financial	A small number of patients seen in private practice. Approximately 3 new patients and 10 follow up patients per year.	1995	On application	Ongoing	Specific. Only a few private patients seen related to thyroid cancer. Declare and participate.
Anh Tran	Committee Member	Direct, non-financial, professional and personal	Member of the NICE Thyroid Guideline Committee (https://www.nice.org.uk/guidance/ng145) published 20 November 2019	December 2017	On application	November 2019	Non-specific Declare and participate.
Anh Tran	Committee Member	Direct, non-financial, professional and personal	Member of the NICE Subarachnoid Haemorrhage Guideline Committee (https://www.nice.org.uk/guidance/indevelopment/gid-ng10097)	October 2018	On application	November 2022	Non-specific Declare and participate.
Anh Tran	Committee Member	Direct, non-financial, professional and personal	GP Member for the update to the British Thyroid Association guidelines for the management of thyroid cancer.	2 May 2019	On application	Ongoing	Specific. The guidelines will be produced collaboratively by consensus. Declare and participate.

